<DOC>
	<DOCNO>NCT00153010</DOCNO>
	<brief_summary>Objectives : The objective study determine safety , tolerability , drug blood level , efficacy three dos NS 2330 ( Tesofensine ) give daily compare placebo patient mild moderate Dementia Alzheimer 's Type .</brief_summary>
	<brief_title>An Evaluation Three Doses NS 2330 Patients With Mild Moderate Dementia Alzheimer 's Type</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<criteria>INCLUSION CRITERIA Patients may include study meet follow criterion : 1 . Male , female without child bear potential 40 85 year age , inclusive . Women postmenopausal less 2 year must negative pregnancy test screening . 2 . Diagnosis probable mild moderate Dementia Alzheimer 's Type define National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association ( NINCDS ADRDA ) guidelines.9 3 . MiniMental State Examination ( MMSE ) score 1024 Alzheimer 's Disease Assessment Scale Cognitive Subscale ( ADASCog ) score great 12 screening . 4 . Modified Hachinski Scale10 score great 4 . 5 . Central nervous system image ( CT MRI scan brain ) compatible Dementia Alzheimer 's Type within past year ( also see exclusion criterion ) . 6 . Exhibits reliability physiologic capability sufficient comply protocol procedure . Patient must familiar fluent English ( i.e. , sufficient complete study assessment language perspective ) . 7 . Patients and/or legal representative caregiver must give informed consent . The legal representative caregiver may person . 8 . Patient must reliable caregiver frequent daily contact patient , accompany patient office monitor administration prescribe medication . The caregiver able communicate English willing comply protocol requirement . EXCLUSION CRITERIA Patients must exclude study meet follow criterion : 1 . Secondary disorder induce dementia neurosyphilis , craniocerebral trauma ( CT/MRI ) , hyperthyroidism , folic acid deficiency . 2 . History malignancy within 3 year , except basal cell carcinoma . 3 . History diagnosis symptomatic and/or unstable/uncontrolled : Cardiovascular illness chronic congestive heart failure ( without edema ) , arrhythmias , labile hypertension , ischemic heart disease , myocardial infarction ( residual angina ) , orthopnea , conduction defect ( ECG ) , heart disease classify NYHA III IV . Liver disease cirrhosis , hepatitis B , hepatitis C , primary metastatic neoplasm . Gastrointestinal disorder GI bleeding , malabsorption syndrome , postgastrectomy , active peptic ulcer disease . Renal disease ( primary secondary ) chronic renal failure ( CLCR &lt; 30 mL/min ) . Endocrine disease diabetes mellitus hypothyroidism . Neurological disease ( Dementia Alzheimer 's Type Huntington 's disease , Parkinson 's disease , encephalitis , epilepsy , stroke , multiple sclerosis ) psychiatric disorder schizophrenia , major depression , mental retardation . Significant pulmonary disease predispose hypoxia . Immunological disorder clinically significant allergy , Lupus erythematosis , scleroderma . Hematological disease ( regardless cause ) refractory anemia refractory myelosuppression . Organ system disease , opinion investigator , would impact primary secondary endpoint trial dehydration ( hematocrit &gt; 48 % ) hypothyroidism . 4 . Significant history drug dependence abuse ( include alcohol , define DSM IV opinion investigator ) within two year , positive urine drug screen cocaine , heroin , marijuana . 5 . HIV positive . 6 . Presence Hepatitis C antibody . 7 . Planned elective surgery require general anesthesia hospitalization 1 day study period . 8 . Previous participation NS 2330 study . 9 . Use investigational drug procedure within 30 day randomization . 10 . Use drug within 14 day prior randomization unless : dose drug condition treat stable least 30 day expect remain stable study neither drug condition treat expect interfere study endpoint . 11 . Treatment donepezil , galantamine , rivastigmine , tacrine , prohibit within 6 week randomization . 12 . Treatment drug inhibit CYP 450 3A4 ( see Appendix II list relevant drug . ) If need emergency condition , patient discontinue trial . 13 . Treatment antipsychotics/neuroleptics prohibit 8 week prior randomisation ( see list Appendix II ) . 14 . Treatment monoamine oxidase inhibitor prohibit 8 week prior randomization . 15 . Treatment selective serotonin reuptake inhibitor prohibit 6 week prior randomization . 16 . Tricyclic antidepressant antihistamine prohibit 4 week prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>